天津医药

• 论著 • 上一篇    下一篇

胶滴肿瘤药敏检测技术在胃癌术后化疗中的应用

李照晋1,谭志军2,姜伟2,韩旭1,张建良1   

  1. 1. 天津医科大学
    2. 天津市第一中心医院
  • 收稿日期:2011-05-11 修回日期:2011-07-29 出版日期:2011-12-15 发布日期:2011-12-15
  • 通讯作者: 李照晋

The application of collagen gel droplet culture drug-sensitivity test (CD-DST) in postoperative chemotherapy of gastric cancer

  • Received:2011-05-11 Revised:2011-07-29 Published:2011-12-15 Online:2011-12-15
  • Contact: Zhao-Jin LI

PDF (PC)

2132

摘要： 目的：探讨胶滴肿瘤药敏检测技术(CD-DST)对胃癌化疗的指导作用及临床应用可行性。方法：将53例胃癌患者的手术标本分别对阿霉素、依托泊苷、奥沙利铂、顺铂、5-氟尿嘧啶、丝裂霉素6种化疗药物进行CD-DST，并将其中对FOLFOX4方案（奥沙利铂、5-氟尿嘧啶和亚叶酸钙）中至少1种药物体外有效者31例作为实验组，未行药敏试验而以FOLFOX4方案作为经验治疗的35例患者作为对照组，2组患者均给予FOLFOX4方案化疗，观察并比较2组患者的术后1年和3年生存率及不良反应发生率。 结果：（1）6种药物均有敏感患者；8例患者对任6种药物均不敏感，26例（49.1%）只对一种药物敏感。（2）实验组和对照组1年生存率（93.5%vs85.7%）差异无统计学意义（P >0.05），3年生存率(83.9%vs60.0%)差异有统计学意义 (P ＜0.05)。 结论：CD-DST技术对于胃癌个体化治疗的化疗方案选择具有一定指导意义。

关键词: 药物筛选试验, 抗肿瘤, 胃肿瘤, 癌, 抗肿瘤联合化疗方案

Abstract: Objective: Observe and value the efficacy of postoperative chemotherapy for gastric cancer under the guidance of CD-DST Technology. Discuss its guiding role and feasibility for chemotherapy of gastric cancer. Methods: The patients who have been confirmed to be effective in vitro with FOLFOX4 by CD-DST enter pilot group， and the patients who have accepted FOLFOX4 without CD-DST enter control group. Compare postoperative one year and three years survival rate between the two groups. Results: In pilot group, year survival rate was 93.5%; three-year survival rate was 83.9%. In control group, year survival rate was 88.6%; three-year survival rate was 60.0%. The difference of three-year survival rate between two groups is significant in statistics. (P﹤0.05) Conclusion: CD-DST technology has some significance for the choice of chemotherapy program for individual treatment of gastric cancer patients.